Pharmacokinetics and safety of montelukast oral granules in children 1 to 3 months of age with bronchiolitis

Journal of Clinical Pharmacology

Volumn 48, Issue 4, 2008, Pages 502-511

  Kearns, Gregory L ^a,b   Lu, Susan ^c   Maganti, Lata ^c   Li, Xiujiang ^c   Migoya, Elizabeth ^c   Ahmed, Tuli ^c   Knorr, Barbara ^c   Reiss, Theodore F ^c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bronchiolitis; Infants; Montelukast; Pharmacokinetics; Safety

Indexed keywords

MONTELUKAST; PLACEBO;

AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; BRONCHIOLITIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM;

ACETATES; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; ASTHMA; BRONCHIOLITIS; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; MALE; NONLINEAR DYNAMICS; POWDERS; QUINOLINES;

EID: 40749110302     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008314251     Document Type: Article

References (38)

1. Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006 ; 117: 1774-1793.
2. Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics. 2004 ; 113: 1758-1764.
3. Henrickson KJ, Hoover S., Kehl KS, Hua WM National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J. 2004 ; 23: S11 - S18.
4. Leader S., Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002 ; 21: 629-632. 5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 ; 282: 1440-1446.
5. Parrot RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, DC. II. Infection and disease with respect to age, immunologic status, race, and sex. Am J Epidemiol. 1973 ; 98: 289-300.
6. Korppi M., Reijonen T., Poysa L., Juntunenbackman K. A 2-year to 3-year outcome after bronchiolitis. Am J Dis Child. 1993 ; 147: 628-631. 8. Coffin SE Bronchiolitis: in-patient focus. Pediatr Clin N Am. 2005 ; 52: 1047-1057.
7. Sigurs N., Gustafsson PM, Bjarnason R., et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med. 2005 ; 171: 137-141.
8. Welliver RC RSV and chronic asthma. Lancet. 1995 ; 34: 789-790. 11. Hyvarinen M., Piippo-Savolainen E., Korhonen K., Korppi M. Teenage asthma after severe infantile bronchiolitis or pneumonia. Acta Paediatr. 2005 ; 94: 1378-1383.
9. Gomez R., Colas C., Sebastian A., Arribas J. Respiratory repercussions in adults with a history of infantile bronchiolitis. Ann Allergy Asthma Immunol. 2004 ; 93: 447-451.
10. Korppi M., Piippo-Savolainen E., Korhonen K., Remes S. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol. 2004 ; 38: 155-160.
11. Welliver R., Obot N., Hintz K. Cysteinyl leukotrien (LT) release correlates with outflow obstruction in experimental respiratory syncytial virus (RSV) infection. Am J Respir Crit Care Med. 2002 ; 165: A458.
12. Volovitz B., Faden H., Ogra PL Release of leukotriene C4 in respiratory tract during acute viral infection. J Pediatr. 1988 ; 112: 218-222.
13. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC II, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol. 1999 ; 103: 630-636.
14. Wedde-Beer K., Hu C., Xu M., Piedmonte G. Respiratory syncytial virus induces 5-lipoxygenase expression and leukotriene production in lungs of weaning rats. Am J Respir Crit Care Med. 2002 ; 165: A458.
15. Knorr B., Holland S., Schwartz J., Rogers JD, Reiss TF Clinical pharmacology of montelukast. Clin Exp Allergy Rev. 2001 ; 1: 254-260.
16. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE Developmental pharmacology drug disposition, action, and therapy in infants and children. New Engl J Med. 2003 ; 349: 1157-1167.
17. Hakkola J., Tanaka E., Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol. 1998 ; 82: 209-217.
18. Hines RN, McCarver DG The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2006 ; 300: 355-360.
19. Kearns GL Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000 ; 106: S128 - S138.
20. Bisgaard H., for the Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003 ; 167: 379-383.
21. Migoya E., Kearns GL, Hartford A., et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol. 2004 ; 44: 487-494.
22. Knorr B., Maganti L., Ramakrishnan R., Tozzi CA, Migoya E., Kearns G. Pharmacokinetics and safety of montelukast in children aged 3 to 6 months. J Clin Pharmacol. 2006 ; 46: 620-627.
23. Singulair [prescribing information]. Whitehouse Station, NJ: Merck & Co Inc ; 2007.
24. Nguyen H., Zhang Z., Larson P., Knorr B. Use of the population 1-compartment model to design a study to best estimate the AUC with limited number of time points per patient. Clin Pharmacol Ther. 1998 ; 63: 195.
25. Knorr B., Holland S., Schwartz J., Rogers JD, Reiss TF Clinical pharmacology of montelukast. Clin Exp Allergy Rev. 2001 ; 1: 254-260.
26. Chiba M., Xu X., Nishime JA, Balani SK, Lin JH Hepatic microsomal metabolism of montelukast, a potent leukotriene D-4 receptor antagonist, in humans. Drug Metab Dispos. 1997 ; 25: 1022-1031.
27. Lacroix D., Sonnier M., Moncion A., Cheron G., Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 1997 ; 247: 625-634.
28. de Wildt SN, Kearns GL, Leeder JS, van den Anker J. Cytochrome P450 3A. Clin Pharmacokinet. 1999 ; 37: 485-505.
29. Hakkola J., Tanaka E., Pelkonen O. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol. 1998 ; 82: 209-217.
30. Hines RN, McCarver DG The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther. 2006 ; 300: 355-360.
31. Kearns GL Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000 ; 106: S128 - S138.
32. Blake MJ, Castro L., Leeder JS, Kearns GL Ontogeny of drug-metabolizing enzymes in the neonate. Semin Fetal Neonatal Med. 2005 ; 10: 123-138.
33. Koukouritaki SB, Manro JR, Marsh SA, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther. 2004 ; 308: 965-974.
34. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN Glucuronidation in humans: pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999 ; 36: 439-452.
35. McCarver DG, Hines RN The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther. 2002 ; 300: 361-366.
36. Kearns GL, Robinson PK, Wilson JT, et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther. 2003 ; 74: 312-325.
37. Bisgaard H., Malice M-P., Marchal J-L., Reiss TF, Knorr BA Randomized, placebo-controlled study of montelukast for treatment of post-RSV-bronchiolitic respiratory symptoms in children. Abstract presented at: XXVI EAACI Congress ; June 9-13, 2007 ; Göteborg, Sweden.
38. van Adelsberg J., Moy J., Wei LX, Tozzi CA, Knorr B., Reiss T. Safety, tolerability, and exploratory efficacy of montelukast in 6-to 24-month-old patients with asthma. Curr Med Res Opin. 2005 ; 21: 971-979.